GlaxoSmithKline PLC Enterprise Value Over Time

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;padding-top: 25px;;'>GP</div>
GSK -- USA Stock  

Report: 22nd of July 2020  

With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets. Please check GlaxoSmithKline PLC Performance and GlaxoSmithKline PLC Correlation.

Search Competitors Fundamentals Over Time Against Enterprise Value

 
Refresh
The current Enterprise Value over EBIT is estimated to increase to 21.06. The current Enterprise Value over EBITDA is estimated to increase to 19.76.

Specify up to 10 symbols:


Cross Equities Enterprise Value Analysis

Compare GlaxoSmithKline PLC and related stocks such as GW Pharmaceuticals Plc, Novartis AG, Grifols S A, Eli Lilly And, Gilead Sciences, Johnson Johnson, Merck Inc, Bristol Myers Squibb, Astrazeneca PLC, and Enterprise Value Over Time
Select Fundamental

20102011201220132014201520162017201820192020
2.7 B2.7 B2.7 B2.7 B2.7 B2.7 B2.7 B2.7 B2.7 B2.4 B2.4 B
128.6 B148.6 B168.9 B208.7 B236.1 B213.8 B190.2 B216.1 B218.5 B237.7 B236.3 B
4.5 B4.5 B12.2 B14.9 B14.6 B14.7 B15.3 B20.1 B19 B22.1 B20.5 B
44.6 B48.6 B57.4 B58.4 B79.3 B98.2 B87.1 B102.7 B126.3 B140.3 B120.4 B
39.3 B33.7 B62.9 B120.5 B145.4 B154.1 B111.6 B111.3 B93.7 B97.3 B103.9 B
181.8 B181.8 B322.2 B322.2 B322.2 B322.2 B322.2 B394.8 B396.6 B394.8 B367.5 B
64.3 B118.8 B126.7 B158.8 B178.4 B166.7 B179.5 B172.4 B214.5 B249.8 B223.5 B
50.2 B60.9 B59.7 B93 B100.7 B118.1 B101.1 B104.1 B86.7 B99.1 B100.4 B
71.4 B64.8 B66 B76.8 B93.3 B92.6 B83.7 B101.6 B113.7 B143.5 B126.9 B
124.5 B133.3 B124.1 B165.2 B135.4 B130.3 B118.9 B112.4 B121.1 B156 B157.7 B

GlaxoSmithKline PLC and related stocks such as GW Pharmaceuticals Plc, Novartis AG, Grifols S A, Eli Lilly And, Gilead Sciences, Johnson Johnson, Merck Inc, Bristol Myers Squibb, Astrazeneca PLC, and Enterprise Value description

Enterprise Value (or EV) is usually referred to as GlaxoSmithKline PLC theoretical takeover price. In the event of an acquisition, an acquirer would have to take on GlaxoSmithKline PLC debt, but would also pocket its cash. Enterprise Value is more accurate representation of GlaxoSmithKline PLC value than its market capitalization because it takes into account all of GlaxoSmithKline PLC existing debt. Enterprise value is a measure of the value of a business as a whole; calculated as Market Capitalization plus Total Debt USD minus Cash and Equivalents USD.

My Equities

My Current Equities and Potential Positions

GSK - USA Stock
GlaxoSmithKline PLC
<div class='circular--portrait-small' style='font-weight: 700;background:#754DEB;color: #F0FFF0;font-size:1.1em;padding-top: 10px;;'>GP</div>
GlaxoSmithKline PLC Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
RegionEurope
ExchangeBATS Exchange
$40.38
Please check GlaxoSmithKline PLC Performance and GlaxoSmithKline PLC Correlation. Please also try Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page